Physician profile
Rehman Sheikh
NPI 1558620351
$3,820.39
in general payments reported to CMS, 2019-2025
21 companies · $611 in 2025
The $611 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $203 · 2021: $82.56 · 2022: $826 · 2023: $683 · 2024: $908 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,183 · Education: $19.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.53 |
| Education | $19.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,031.06 | 2019-2025 | Rinvoq, Mavyret, Linzess |
| Janssen Biotech, INC. | $561.84 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $432.20 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.68 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $233.25 | 2022-2023 | Zeposia |
| Conmed Corporation | $195.23 | 2022-2025 | Conmed Generators, Conmed Dilation |
| Genzyme Corporation | $169.62 | 2022-2025 | |
| Lilly USA, LLC | $146.81 | 2024 | Omvoh |
| Boston Scientific Corporation | $127.72 | 2023 | Wallflex Duodenal |
| Qol Medical, LLC | $124.99 | 2020 | |
| Aries Pharmaceuticals, INC. | $100.45 | 2019 | |
| Cook Medical LLC | $69.25 | 2019 | |
| Intercept Pharmaceuticals, INC. | $58.07 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $48.06 | 2022-2023 | Dificid |
| Madrigal Pharmaceuticals | $40.44 | 2025 | Rezdiffra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $38.79 | 2019-2020 | |
| Shionogi INC | $33.61 | 2019 | |
| Ironwood Pharmaceuticals, INC | $33.11 | 2020-2022 | |
| Celgene Corporation | $17.89 | 2024 | Zeposia |
| Shire North American Group INC | $15.14 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.18 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rehman Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.